Merus N.V.
Clinical trials sponsored by Merus N.V., explained in plain language.
A clinical-stage biopharmaceutical company developing bispecific antibody therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New hope for head and neck cancer: experimental drug petosemtamab enters final testing
Disease control OngoingThis Phase 3 trial tests a new drug called petosemtamab against standard treatments (cetuximab, methotrexate, or docetaxel) in 600 adults with advanced head and neck cancer that has spread or come back. Participants must have already tried immunotherapy and chemotherapy. The main…
Phase 3 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug duo aims to shrink lung tumors in First-Line trial
Disease control CancelledThis phase 2 trial tests whether adding petosemtamab to the standard immunotherapy pembrolizumab can shrink tumors in adults with metastatic non-small cell lung cancer. About 180 participants will receive the combination as their first treatment. The study focuses on how many pat…
Phase 2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New dual-action antibody enters early trials for tough-to-treat cancers
Disease control OngoingThis early-phase study tests an experimental drug called MCLA-129, a bispecific antibody that targets two cancer-related proteins (EGFR and c-MET). It is for people with advanced non-small cell lung cancer, gastric cancer, esophageal cancer, head and neck cancer, or colorectal ca…
Phase 1/2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC